You can buy or sell ArQule and other stocks, options, ETFs, and crypto commission-free!
ArQule, Inc. Common Stock, also called ArQule, is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. Read More The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.
52 Week High
52 Week Low
Research And Development
Markets InsiderMar 15
ArQule Announces Management Team Changes
ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial Officer and Head of Strategy, effective as of Mr. Weiskopf’s retirement. Dr. Schegerin joined ArQule in May 2018 and most recently served as Senior Vice President, Head of Strategy, Finance and Communication. "Rob has played a ...
ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule....
ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and...
Expected May 6, Pre-Market